Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to 17.58%.

  • Cytek Biosciences' EBIT Margin fell 93300.0% to 17.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.16%, marking a year-over-year decrease of 44100.0%. This contributed to the annual value of 10.24% for FY2024, which is 41900.0% up from last year.
  • Latest data reveals that Cytek Biosciences reported EBIT Margin of 17.58% as of Q3 2025, which was down 93300.0% from 23.3% recorded in Q2 2025.
  • Cytek Biosciences' 5-year EBIT Margin high stood at 12.53% for Q2 2021, and its period low was 36.12% during Q1 2025.
  • Moreover, its 5-year median value for EBIT Margin was 6.72% (2022), whereas its average is 8.6%.
  • Per our database at Business Quant, Cytek Biosciences' EBIT Margin skyrocketed by 136700bps in 2021 and then crashed by -260700bps in 2023.
  • Over the past 5 years, Cytek Biosciences' EBIT Margin (Quarter) stood at 3.39% in 2021, then tumbled by -95bps to 0.17% in 2022, then crashed by -235bps to 0.24% in 2023, then skyrocketed by 2308bps to 5.2% in 2024, then tumbled by -438bps to 17.58% in 2025.
  • Its EBIT Margin stands at 17.58% for Q3 2025, versus 23.3% for Q2 2025 and 36.12% for Q1 2025.